Physician profile
Christine Blake Smith
NPI 1760531180
$22,498.94
in general payments reported to CMS, 2019-2025
48 companies · $2,335 in 2025
The $2,335 reported for 2025 was more than what 93% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,283 · 2020: $2,130 · 2021: $3,065 · 2022: $3,549 · 2023: $4,190 · 2024: $3,946 · 2025: $2,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,198.69 |
| Education | $273.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,507.00 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $2,775.13 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,395.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,343.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,317.61 | 2019-2025 | Trelegy Ellipta |
| Grifols USA, LLC | $1,151.72 | 2019-2024 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $975.95 | 2019-2024 | Trintellix |
| Novo Nordisk INC | $901.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $807.22 | 2019-2023 | Synjardy, Jardiance |
| Teva Pharmaceuticals USA, INC. | $741.16 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Amgen INC. | $698.35 | 2019-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $528.17 | 2019-2025 | Gardasil 9, Verquvo, Capvaxive |
| Dexcom, INC. | $492.21 | 2023-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $409.51 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $361.68 | 2021-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.